全球智库信息集成服务系统(G2TT): The Opportunities and Limitations of Monopsony Power in Healthcare: Evidence from the United States and Canada

G2TT

来源类型	Working Paper
规范类型	报告
DOI	10.3386/w26122
来源ID	Working Paper 26122
	The Opportunities and Limitations of Monopsony Power in Healthcare: Evidence from the United States and Canada
	Jillian Chown; David Dranove; Craig Garthwaite; Jordan Keener
发表日期	2019-07-29
出版年	2019
语种	英语
摘要	Perhaps more than any other sector of the economy, healthcare depends on government resources. As a result, many healthcare systems rely on the use of government monopsony power to decrease spending. The United States is a notable exception, where prices in large portions of the healthcare sector are set without government involvement. In this paper we examine the economic implications of a greater use of monopsony power in the United States. We present a model of monopsony power and test its predictions using price differences between the United States and Canada – a country that represents an example of a “Medicare for All” style system. Overall, we find that wage differences for medical providers across the two countries are primarily driven by the broader labor market while price difference for prescription drugs are more directly the result of buyer power. We discuss theoretical reasons why a Canadian monopsonist may be more willing to exploit its buyer power over prescription drugs rather than provider wages and why a U.S. monopsonist might not be willing to do the same
主题	Public Economics ; Public Goods ; Health, Education, and Welfare ; Health
URL	https://www.nber.org/papers/w26122
来源智库	National Bureau of Economic Research (United States)
引用统计
资源类型	智库出版物
条目标识符	http://119.78.100.153/handle/2XGU8XDN/583794
推荐引用方式 GB/T 7714	Jillian Chown,David Dranove,Craig Garthwaite,et al. The Opportunities and Limitations of Monopsony Power in Healthcare: Evidence from the United States and Canada. 2019.

条目包含的文件
文件名称/大小	资源类型	版本类型	开放类型	使用许可
w26122.pdf（673KB）	智库出版物		限制开放	CC BY-NC-SA	浏览